(MedPage Today) — The investigational combination of ervogastat plus clesacostat showed efficacy and safety for patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis in the phase II MIRNA…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/116834
Author :
Publish date : 2025-08-05 16:42:00
Copyright for syndicated content belongs to the linked Source.
